Table 2 Respondents’ general knowledge on the safety of conventional synthetic disease modifying anti-rheumatic drugs, biologics/small molecules, and other medications in the management of inflammatory arthritis in pregnancy
Safe throughout pregnancy (% of respondents) | Safe during certain trimesters (% of respondents) | Not safe at all (% of respondents) | Not sure (% of respondents) | |
|---|---|---|---|---|
Conventional synthetic disease modifying anti-rheumatic drugs | ||||
Azathioprine | 80.5* | 4.9 | 12.2 | 2.4 |
Chloroquine | 74.1 | 1.2 | 8.6 | 16.0 |
Cyclophosphamide | 0 | 3.7 | 95.1* | 1.2 |
Cyclosporine | 28.0 | 6.1 | 42.7 | 23.2 |
Doxycycline | 2.4 | 4.9 | 59.8 | 32.9 |
Gold salts | 28.7 | 2.5 | 33.8 | 35.0 |
Hydroxychloroquine | 92.7* | 4.9 | 1.2 | 1.2 |
Leflunomide | 0 | 0 | 97.6* | 2.4 |
Methotrexate | 0 | 1.2 | 97.6* | 1.2 |
Minocycline | 0 | 4.9 | 53.1 | 42.0 |
Mycophenolate mofetil | 2.5 | 2.5 | 81.5* | 13.6 |
Sulfasalazine | 70.4 | 8.6 | 18.5 | 2.5 |
Biologics/small molecules | ||||
Abatacept | 9.8 | 9.8 | 15.9 | 64.6 |
Adalimumab | 37.0 | 32.1 | 6.2 | 24.7 |
Anakinra | 9.9 | 6.2 | 16.0 | 67.9 |
Apremilast | 0 | 1.2 | 18.5 | 80.2* |
Certolizumab | 61.0 | 15.9 | 4.9 | 18.3 |
Etanercept | 43.9 | 29.3 | 7.3 | 19.5 |
Golimumab | 37.8 | 25.6 | 11.0 | 25.6 |
Infliximab | 37.8 | 30.5 | 8.5 | 23.2 |
Rituximab | 8.5 | 8.5 | 25.6 | 57.3 |
Tocilizumab | 11.0 | 8.5 | 19.5 | 61.0 |
Tofacitinib | 1.2 | 1.2 | 21.0 | 76.5* |
Ustekinumab | 4.9 | 6.1 | 18.3 | 70.7 |
Other medications | ||||
Celecoxib | 0 | 54.9 | 29.3 | 15.9 |
Ibuprofen | 1.2 | 83.6* | 14.5 | 1.2 |
Naproxen | 2.4 | 82.9* | 11.0 | 3.7 |
Other NSAIDs | 1.2 | 67.5 | 22.5 | 8.8 |